The table below shows Protagonist Therapeutics, Inc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$48.94M
$125.36M
-$27.43M
-$34.35M
-$37.67M
-$28.76M
Capital expenditure
$215.00K
$545.00K
$242.00K
$10.00K
$273.00K
$140.00K
Investing cash flow
$90.89M
-$94.40M
$6.07M
$9.83M
-$4.48M
-$6.79M
Dividends paid
-
-
-
-
PTGX operating cash flow (10-K history)
Protagonist Therapeutics, Inc reported operating cash flow of $57.67M for fiscal year 2025. That is down 68.7% from $184.15M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$29.97M (FY 2016) to $57.67M. Figures come from the company's audited annual reports as filed with the SEC.